Operator
Welcome to the Implantica Q2 2026 Report Presentation. [Operator Instructions] Now I will hand the conference over to the speakers, CEO, Peter Forsell; CFO, Andreas Öhrnberg; and Chief Corporate Affairs Officer, Nicole Pehrsson. Please go ahead.
Peter Forsell
Founder & CEO
Thank you. So my name is Peter Forsell, the CEO of the company. And I will try to guide you through today’s Q2 presentation. So for those who has not heard this before, I’m a surgeon, and I’m also the inventor of the products we have in Implantica and also the CEO and founder of the company.
And this is the second journey. So the first journey was the gastric band, which I developed and also a business for 6 years that successfully was sold to J&J. And that’s the funding. Part of that has been used for this new Implantica venture. Really the good news for today is, of course, that Implantica has got FDA approval for its product RefluxStop. And that’s, of course, fantastic news because United States is the largest market for medical products overall. And it’s also a country who is more positive to new technology and also willing to pay for new technology.
And the good thing here is that we have 1 billion sufferers whereas 78 million we have in the United States. So it’s enormous amount of people have this disease. It’s larger than obesity basically. So I will come back to the FDA approval because I think today, we have quite many new business. So I will just
